Anticipating Key Studies and Pipeline Treatments in mCRC Landscape
The experts provide their final thoughts surrounding the impact of prospective trials and therapy regimens for treating patients with refractory mCRC.
Read More
Treatment Sequencing for Refractory mCRC and SUNLIGHT Study Analysis
Data presented at ESMO 2023 and ASCO GI 2024 highlight the impact of prior therapy, including VEGF inhibitors or fluoropyrimidine, on mCRC treatment approach.
Read More
Considerations for Platinum-based Therapy
Key factors, particularly neuropathy, drive the discussion for platinum-based therapy for patients with non-refractory mCRC.
Read More
Identifying Ideal Candidates for Triplet Therapy in mCRC Treatment
Considerations for patients to receive aggressive mCRC therapy regimens are navigated by the panelists.
Read More
Utilizing RWE to Derive Optimal Treatment Strategy for Refractory mCRC
Richard Kim, MD, discusses the significance of real-world evidence when selecting treatment sequencing strategy.
Read More
Dose Modifications and Tolerability Associated with mCRC Treatment Regimens
Managing dose adjustments and tolerability in metastatic colorectal cancer (mCRC) treatment regimens for optimal efficacy is underscored.
Read More
Compounding Impact of TAS-102 and Bevacizumab in mCRC Treatment
Marwan G Fakih, MD, drives a discussion highlighting a significant combination therapy in mCRC treatment.
Read More
Overview of Current mCRC Treatment Landscape
Medical experts open a discussion providing an update on the current impact of metastatic colorectal cancer and common treatment strategies.
Read More
Metastatic Colorectal Cancer: Ongoing Challenges and Future Directions in Care
Closing out their panel on metastatic colorectal cancer, expert oncologists consider ongoing challenges and future evolutions within the treatment landscape.
Read More
HER2+ Metastatic Colorectal Cancer: Clinical Trial Data With T-DXd
Focused discussion on clinical trial data with trastuzumab deruxtecan in the setting of HER2+ metastatic colorectal cancer.
Read More
HER2+ Metastatic Colorectal Cancer: Clinical Trial Data With Tucatinib
A panel of oncologists shares comprehensive insight to clinical trial data with tucatinib in patients with HER2+ metastatic colorectal cancer.
Read More
Assessing HER2 Expression in Metastatic Colorectal Cancer
Switching their focus to HER2+ metastatic colorectal cancer, panelists discuss best practices in testing HER2 to aid in the timely selection of best available therapies.
Read More
Novel Combination Strategies in BRAF-Mutant Metastatic Colorectal Cancer
Expert perspectives on novel combination and immunotherapy strategies within BRAF-mutated metastatic colorectal cancer management.
Read More
Metastatic Colorectal Cancer: Tumor Sidedness and EGFR-Targeted Therapy
Shared insight to the importance of tumor sidedness and its impact on the selection of EGFR-targeted therapy in metastatic colorectal cancer.
Read More
BRAF V600E–Mutant Metastatic Colorectal Cancer: BREAKWATER Study
Key opinion leaders in metastatic colorectal cancer management review data from the BREAKWATER study in BRAF-V600E–mutated disease.
Read More
Treatment Options for BRAF V600E–Mutant Metastatic Colorectal Cancer
Centering discussion on patients with BRAF-V600E mutations in metastatic colorectal cancer, panelists reflect on the treatment armamentarium in this setting.
Read More
Colorectal Cancer: Evolving Role of ctDNA Testing in Practice
A brief review of how circulating tumor DNA testing has impacted the real-world management of patients with metastatic colorectal cancer.
Read More
ctDNA and MRD Testing in Nonmetastatic Colorectal Cancer
A focused discussion on the respective roles of circulating tumor DNA and minimal residual disease testing in the management of patients with nonmetastatic colorectal cancer.
Read More
Biomarker Testing in Metastatic Colorectal Cancer
Expert panelists provide their perspective on the current state of molecular testing in metastatic colorectal cancer and how it impacts treatment pathways.
Read More
Audience Q&A: Best Practices in Managing HER2-Amplified CRC
Fielding questions from the audience, expert oncologists discuss clinical trials, molecular testing, and early-stage disease in the context of HER2-amplified colorectal cancer.
Read More
Evolutions in the HER2-Amplified CRC Treatment Landscape
Looking toward the future management of HER2-amplified colorectal cancer, panelists reflect on ongoing clinical trials and evolving treatment strategies.
Read More
Real-World Use of HER2-Directed Therapies in Colorectal Cancers
Expert perspectives on the real-world use of HER2-directed therapies in patients with HER2-amplified colorectal cancer.
Read More